4//SEC Filing
Campbell David Alan 4
Accession 0001415889-24-025792
CIK 0001817713other
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 7:30 PM ET
Size
7.2 KB
Accession
0001415889-24-025792
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-10-28$53.22/sh−13,897$739,650→ 293,157 total - Sale
Common Stock
2024-10-28$53.94/sh−11,103$598,909→ 282,054 total
Footnotes (3)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001864158
Filing Metadata
- Form type
- 4
- Filed
- Oct 29, 8:00 PM ET
- Accepted
- Oct 30, 7:30 PM ET
- Size
- 7.2 KB